MedTrace Logo

Post-transplant Cyclophosphamide in Wiskott-Aldrich Syndrome

NCT03198195 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2017-06-27

No results posted yet for this study

Summary

A protocol named as "CIP-2015" for patients with Wiskott-Aldrich Syndrome may reduce the rate of GvHD.

The details of the protocal followed with:

1. Conditioning regimen Busulfan 16 mg/kg in total, Fludarabine 160 mg/m2 in total.
2. GvHD Prophylaxis:

Rabbit antihuman thymocyte globulin 7.5 mg/kg post-transplant cyclophosphamide (CY) (50 mg/kg.d on days +3 and +4) Cyclosporine or tacrolimus, mycophenolate mofetil, on days +5

Conditions

  • Wiskott-Aldrich Syndrome

Interventions

PROCEDURE

cyclophosphamide

on days +3，+4,using cyclophosphamide 50mg/kg

Sponsors & Collaborators

  • Capital Research Institute of Pediatrics

    lead OTHER_GOV

Eligibility

Min Age
5 Months
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-10
Primary Completion
2017-03-10
Completion
2020-07-10

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03198195 on ClinicalTrials.gov